Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64

Nature Protocols

Volumn 1, Issue 6, 2006, Pages 3062-3068

  Wadas, Thaddeus J ^a   Anderson, Carolyn J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548864369     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2006.431     Document Type: Article

References (45)

1. Wadas, T.J., Wong, E.H., Weisman, G.R. & Anderson, C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des. (in the press).
2. Smith, S.V. Molecular imaging with copper-64. J. Inorg. Biochem. 98, 1874-1901 (2004).
3. Mountz John, D. et al. Molecular imaging: New applications for biochemistry. J. Cell. Biochem. Suppl. 39, 162-171 (2002).
4. Rowland, D.J., Lewis, J.S. & Welch, M.J. Molecular imaging: The application of small animal positron emission tomography. J. Cell. Biochem. Suppl. 39, 110-115 (2002).
5. Blok, D., Feitsma, R.I.J., Vermeij, P. & Pauwels, E.J.K. Peptide radiopharmaceuticals in nuclear medicine. Eur. J. Nucl. Med. 26 1511-1519 (1999).
6. Okarvi, S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur. J. Nucl. Med. 28, 928-938 (2001).
7. Signore, A. et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur. J. Nucl. Med. 28, 1555-1565 (2001).
8. Sun, X. & Anderson, C.J. Production and applications of copper-64 radiopharmaceuticals. Meth. Enzymol. 386, 237-261 (2004).
9. Anderson, C.J. & Welch, M.J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 99, 2219-2234 (1999).
10. Blower, P.J., Lewis, J.S. & Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl. Med. Biol. 23 957-980 (1996).
11. Hnatowich, D.J., Layne, W.W., Childs, R.L., Lanteigne, D. & Davis, M.A. Radioactive labeling of antibody: A simple and efficient method. Science 220, 613-615 (1983).
12. Parker, D., Morphy, J.R., Jankowski, K. & Cox, J. Implementation of macrocycle-conjugated antibodies for tumor-targeting. Pure Appl. Chem. 61 (9): 1637-1641 (1990).
13. 57Co. Nucl. Med. Biol. 13, 363-368 (1986).
14. Yeh, S.M., Sherman, D.G. & Meares, C.F. A new route to 'bifunctional' chelating agents: Conversion of amino acids to analogs of ethylenedinitrilotetraacetic acid. Anal. Biochem. 100, 152-159 (1979).
15. Meares, C.F. & Wensel, T.G. Metal chelates as probes of biological systems. Acc. Chem. Res. 17, 202-209 (1984).
16. Moi, M.K., Meares, C.F., McCall, M.J., Cole, W.C. & DeNardo, S.J. Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem. 148 249-253 (1985).
17. Cole, W.C. et al. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med. 28, 83-90 (1987).
18. Meares, C.F. et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br. J. Cancer Suppl. 10, 21-26 (1990).
19. Kukis, D.L., Li, M. & Meares, C.F. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg. Chem. 32, 3981-3982 (1993).
20. (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718 (2005).
21. Li, W.P., Lewis, J.S., Srinivasan, A., Schmidt, M.A. & Anderson, C.J. Copper-64/61 and iodine-125-labeled DOTA-D-TYR1-octreotate: A new somatostatin analog for labeling with metals and halogens. J. Labelled Comp. Radiopharm. 44 (suppl 1): S948-S950 (2001).
22. 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of α-MSH. J. Med. Chem. 48, 2985-2992 (2005).
23. 3-targeted imaging of lung cancer. Neoplasia 7, 271-279 (2005).
24. 3 integrin expression using F-18 and Cu-64-labeled RGD peptides. Bioconjug. Chem. 15, 41-49 (2004).
25. 3-integrin expression. J. Nucl. Med. 45, 1776-1783 (2004).
26. 2. J. Nucl. Med. 36, 850-858 (1995).
27. Anderson, C.J. et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J. Nucl. Med. 39, 1944-1951 (1998).
28. Anderson, C.J. et al. Copper-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 42 213-221 (2001).
29. 3-octreotate. A new somatostatin analog with improved target tissue uptake. Nucl. Med. Biol. 26, 267-273 (1998).
30. 64Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for PET imaging and targeted radiotherapy. J. Med. Chem. 42, 1341-1347 (1999).
31. 64Cu-BAT-2IT-1A3. Cancer Biother. Radiopharm. 16, 483-494 (2001).
32. Cutler, P.D. et al. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J. Nucl. Med. 36, 2363-2371 (1995).
33. Wang, M. et al. Subcellular localization of somatostatin analogues: Implications for targeted radiotherapy of cancer. Cancer Res. 63, 6864-6869 (2003).
34. Edwards, W.B., Anderson, C.J., Fields, G.B. & Welch, M.J. Evaluation of type IV collagen fragments as potential tumor imaging agents. Bioconjug. Chem. 12, 1057-1065 (2001).
35. Weisman, G.R., Rogers, M.E., Wong, E.H., Jasinski, J.P. & Paight, E.S. Cross-bridged cyclam. Protonation and Li+ complexation in a diamond-lattice cleft. J. Am. Chem. Soc. 112, 8604-8605 (1990).
36. Weisman, G.R. et al. Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands. J. Chem. Soc. Chem. Commun., 947-948.
37. Niu, W. et al. Copper(II) and zinc(II) complexes of amide pendant-armed cross-bridged tetraamine ligands. Polyhedron 23 1019-1025 (2004).
38. Wong, E.H. et al. Synthesis and characterization of crossbridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes. J. Am. Chem. Soc. 122, 10561-10572 (2000).
39. Woodin, K.S. et al. Kinetic inertness and electrochemical behavior of copper(II) tetraazamacrocyclic complexes: Possible implications for in vivo stability. Eur. J. Inorg. Chem. 23, 4829-4833 (2005).
40. Boswell, C.A. et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J. Med. Chem. 47, 1465-1474 (2004).
41. Sun, X. et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J. Med. Chem. 45, 469-477 (2002).
42. Sprague, J.E. et al. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin. Cancer Res. 10, 8674-8682 (2004).
43. Wadas, T.J., Wong, E.H., Weisman, G.R. & Anderson, C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Design 13, 3-16 (2007).
44. Edwards, W.B. Cancer Imaging with PET. Ph.D. Thesis, Washington University in St. Louis (1999).
45. Mant, C.T. & Hodges, R.S. High-Performance Liquid Chromatography of Peptides and Proteins: Separation, Analysis, and Conformation (CRC Press, Boca Raton, Florida, 2000).